|drug1446||Halo Oral Spray Wiki||1.00|
|drug1447||Halo Placebo Wiki||1.00|
|D003141||Communicable Diseases NIH||0.08|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
This is a multi-center, double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating NORS for the treatment of COVID-19 in individuals with Suspected mild COVID-19 Infection.
Description: Number of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms in NORS vs placebo groupMeasure: To Measure the efficacy of NORS compared to saline placebo in the hospitalization of participants with mild COVID-19 infection Time: 28 Days
Description: Measure the change in mean Modified Jackson Cold Score Diary ScoreMeasure: To Measure reduction of clinical symptoms as compared to saline placebo in participants with mild COVID-19 infection Time: 7, 14, 21 and 28 days
Description: Number of participants lost-to-follow-up,discontinuing study treatment or number of treatments due to intoleranceMeasure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection Time: 14 days
Description: Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.Measure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports